NEW YORK, May 8 - Vertex Pharmaceuticals has contracted with Deltagen for access to part of DeltaBase, the companies said Tuesday.
The subscription will allow Vertex to obtain in vivo mammalian gene function on kinases, proteases, and other commercially-relevant gene families, according to a statement.
Vertex will have intellectual property rights to commercialize pharmaceutical products based on the research. In exchange, Deltagen will receive milestone and royalty payments. The agreement is for three years, with the option to extend for an additional two.
In a subscription arrangement with Pfizer signed last year, Deltagen charged $15 million for a three-year license. GlaxoSmithKline also has a subscription for DeltaBase, a database of functional and phenotypic information on mammalian genes obtained from mouse models.
"This genomic information will contribute to our biological understanding of specific proteins within several target-rich gene families, and will complement our parallel, small molecule drug design programs," Vicki Sato, president of Vertex, said in a statement.
Last week, Vertex acquired Aurora Biosciences, a manufacturer and provider of cell-based assay and high-throughput testing systems, for $592 million in stock.